Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inovio Pharma (NQ: INO )

5.450 +0.170 (+3.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inovio Pharma

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Inovio Pharmaceuticals Is Plunging Today
Solid business developments did not please investors. 
Via The Motley Fool
Exposures COVID-19
Why Inovio's Stock Is Trading Lower Today
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading lower by 9.9% at $8.65 after the company reported worse-than-expected second-quarter EPS and sales results.... 
Via Benzinga
54 Stocks Moving In Tuesday's Mid-Day Session
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy... 
Via Benzinga
Analyzing Inovio Pharmaceuticals's Unusual Options Activity
Inovio Pharmaceuticals (NASDAQ:INO) shares experienced unus... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Inovio Pharmaceuticals (INO) Q2 2021 Earnings Call Transcript
INO earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Inovio Pharmaceuticals Q2 Earnings
Shares of Inovio Pharmaceuticals (NASDAQ:INO) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 95.00% year... 
Via Benzinga
Why Inovio Stock Is Jumping Today
Chinese regulators approved the initiation of two new clinical studies featuring Inovio's COVID-19 vaccine candidate, INO-4800. 
Via The Motley Fool
Exposures COVID-19
What Does the Delta Variant Mean for Inovio Pharmaceuticals' Stock?
Its vaccine candidate might be too far behind to matter. 
Via The Motley Fool
Exposures COVID-19
Is Inovio Pharmaceuticals Primed For a Comeback?
The past 12 months have been tough on the vaccine maker. 
Via The Motley Fool
Exposures COVID-19
Here's Why Inovio Pharmaceuticals Soared 23% In June
Encouraging news reversed what had been a steep sell-off for the clinical-stage biotech. 
Via The Motley Fool
Exposures COVID-19
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021
Upgrades Zelman upgraded the previous rating for Armstrong World Industries Inc (NYSE: 
Via Benzinga
Inovio Pharmaceuticals: Return On Capital Employed Insights
During Q1, Inovio Pharmaceuticals's (NASDAQ:INO) reported sales totaled $371.12 thousand. Despite a 79.13% in earnings, the company posted a loss of $52.55 million. In Q4, Inovio... 
Via Benzinga
Inovio Pharmaceuticals Could See a Boost from Covid-19 Partnerships
Some say INO stock could be the target of a short squeeze, but Inovio's Covid-19 vaccine program should be a sufficient reason to invest. 
Via InvestorPlace
Exposures COVID-19
Should You Buy Biotech ETFs Now?
Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and... 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers NuCana (NASDAQ:NCNA) shares moved upwards by 16.17% to $3.16 during Thursday's regular session. NuCana's stock is trading at a volume of 4.7 million shares... 
Via Benzinga
Why Inovio Stock Is Sinking Today
Investors appear to be taking some profits after yesterday's huge gain. 
Via The Motley Fool
Exposures COVID-19
Twitter And Regeneron Lead The SPY In Another Mixed Day Of Trading
U.S. indices at a mixed day of trading Wednesday as investors and traders weighed the U.S. 30-Year Treasury note falling to 2.1483%,... 
Via Benzinga
Why Inovio Stock Looks Ready To Break Out, Make Bullish Reversal
Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares were trading higher Wednesday as retail traders continue to push high short interest stocks higher. The stock saw above average... 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares surged 388.2% to close at $10.79 on Wednesday in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID... 
Via Benzinga
INO Stock: 2 Big Reasons Inovio Pharmaceuticals Is Shooting Higher Today
Today, INO stock is soaring amid a recently announced expanded partnership for its Covid-19 vaccine and potential short squeeze implications. 
Via InvestorPlace
Exposures COVID-19
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares moved upwards by 347.96% to $9.9 during Wednesday's regular session. As of 12:30 EST, Aethlon Medical's stock is... 
Via Benzinga
48 Stocks Moving In Wednesday's Mid-Day Session
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares jumped 371% to $10.41 in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An... 
Via Benzinga
Inovio Pharmaceuticals Insights: Return On Capital Employed
During Q1, Inovio Pharmaceuticals's (NASDAQ:INO) reported sales totaled $371.12 thousand. Despite a 79.13% in earnings, the company posted a loss of $52.55 million. In Q4, Inovio... 
Via Benzinga
Inovio, Advaccine to Share $100M in Cost for Late-Stage COVID-19 Vaccine Trial
Inovio Pharmaceuticals Inc (NASDAQ: INO) has expanded its partnership with Advaccine Biopharmaceuticals Suzhou Co Ltd to jointly conduct a global... 
Via Benzinga
Exposures COVID-19
These Vaccine Latecomers Could Still Win Big. Here's How
The key is standing out from the crowd. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
Why Inovio Pharmaceuticals Stock Perked Up in May
The biotech's pan-COVID-19 vaccine caught the eye of investors last month. 
Via The Motley Fool
Exposures COVID-19
I Would Hope Inovio Isn’t Attracting ANY Serious Money
It seems as though INO stock will have a tough time getting and staying in double digits 
Via InvestorPlace
Is It Too Late to Buy Inovio Pharmaceuticals Stock?
This troubled coronavirus vaccine developer has created far more woes than joys for investors. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.